All In Biotech

Drug Trial Radar · NCT05970289

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

86

Actual

Start

Aug 22, 2023

Primary completion

Jul 16, 2025

Study completion Jan 23, 2026

Sponsor

Lead sponsor
Brii Biosciences LimitedIndustry
Sponsor type
Industry
Collaborators
Vir Biotechnology, Inc.
First posted
Aug 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.

Conditions

  • Chronic Hepatitis B Virus Infection

Interventions

  • PEG-IFNαBiological

    PEG-IFNα will be given via subcutaneous injection

  • BRII-835Drug

    BRII-835 will be given via subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with HBsAg loss at end of treatmentTime frame: Up to Week 48
  2. Proportion of participants with HBsAg loss at 24 weeks post-end of treatmentTime frame: Up to Week 72
  3. Proportion of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to Week 72
  4. Proportion of participants with serious adverse events (SAEs)Time frame: Up to Week 72

Locations

28 sites in 5 countries. Site status is shown where the registry gives one.

  • Investigative Site 61001

    Kingswood, New South Wales, Australia

  • Investigative Site 61002

    Birtinya, Queensland, Australia

  • Investigative Site 61003

    Melbourne, Victoria, Australia

  • Investigative Site 86001

    Beijing, Beijing Municipality, China

  • Investigative Site 86007

    Beijing, Beijing Municipality, China

  • Investigative Site 86004

    Chongqing, Chongqing Municipality, China

  • Investigative Site 86006

    Guangzhou, Guangdong, China

  • Investigative Site 85201

    Hong Kong, HONG KONG, China

  • Investigative Site 85202

    Hong Kong, HONG KONG, China

  • Investigative Site 86008

    Changchun, Jilin, China

  • Investigative Site 86013

    Shanghai, Shanghai Municipality, China

  • Investigative Site 88601

    Kaohsiung, Taiwan, China

  • Investigative Site 88602

    Taipei, Taiwan, China

  • Investigative Site 88603

    Taipei, Taiwan, China

  • Investigative Site 86011

    Hangzhou, Zhengjiang, China

  • Investigative Site 65001

    Singapore, Singapore, Singapore

  • Investigative Site 65002

    Singapore, Singapore, Singapore

  • Investigative Site 82005

    Seoul, South Korea

  • Investigative Site 82006

    Soeul, South Korea

  • Investigative Site 82001

    Busan, Busan, South Korea

  • Investigative Site 82002

    Chuncheon, CHUNCHEON-SI, South Korea

  • Investigative Site 82004

    Daegu, Daegu, South Korea

  • Investigative Site 82003

    Seoul, Seoul, South Korea

  • nvestigative Site 66007

    Chiang Mai, Thailand

  • Investigative Site 66008

    Songkhla, Thailand

  • Investigative Site 66003

    Bangkok, Bangkok, Thailand

  • Investigative Site 66005

    Khon Kaen, Changwat Khon Kaen, Thailand

  • Investigative Site 66006

    Nonthaburi, Changwat Nonthaburi, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.